Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rachel Jennings is active.

Publication


Featured researches published by Rachel Jennings.


Diabetes | 2013

Development of the human pancreas from foregut to endocrine commitment

Rachel Jennings; Andrew Berry; Rebecca Kirkwood-Wilson; Neil A. Roberts; Thomas Hearn; Rachel J. Salisbury; Jennifer Blaylock; Karen Hanley; Neil A. Hanley

Knowledge of human pancreas development underpins our interpretation and exploitation of human pluripotent stem cell (PSC) differentiation toward a β-cell fate. However, almost no information exists on the early events of human pancreatic specification in the distal foregut, bud formation, and early development. Here, we have studied the expression profiles of key lineage-specific markers to understand differentiation and morphogenetic events during human pancreas development. The notochord was adjacent to the dorsal foregut endoderm during the fourth week of development before pancreatic duodenal homeobox-1 detection. In contrast to the published data from mouse embryos, during human pancreas development, we detected only a single-phase of Neurogenin 3 (NEUROG3) expression and endocrine differentiation from approximately 8 weeks, before which Nirenberg and Kim homeobox 2.2 (NKX2.2) was not observed in the pancreatic progenitor cell population. In addition to revealing a number of disparities in timing between human and mouse development, these data, directly assembled from human tissue, allow combinations of transcription factors to define sequential stages and differentiating pancreatic cell types. The data are anticipated to provide a useful reference point for stem cell researchers looking to differentiate human PSCs in vitro toward the pancreatic β-cell so as to model human development or enable drug discovery and potential cell therapy.


Hormone Research in Paediatrics | 2010

GH/IGF-I regulation in obesity--mechanisms and practical consequences in children and adults

Ilonka Kreitschmann-Andermahr; Pablo Suarez; Rachel Jennings; Nina Evers; Georg Brabant

Growth hormone (GH) secretion in children and adults is profoundly, but reversibly, suppressed in obesity. Since GH deficiency leads to increased fat mass, differentiation of both conditions remains challenging. Here we review the known and still speculative mechanisms underlying the inhibitory effects of obesity on GH secretion including peripheral factors like IGF-I and insulin, as well as central hypothalamic/pituitary modulators. We further discuss the basis of current testing for GH deficiency in obesity and the validity of the various provocative tests in overweight subjects.


Nature Cell Biology | 2015

TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors

Inês Cebola; Santiago A. Rodríguez-Seguí; Candy H.-H. Cho; José Bessa; Meritxell Rovira; Mario Luengo; Mariya Chhatriwala; Andrew Berry; Joan Ponsa-Cobas; Miguel Angel Maestro; Rachel Jennings; Lorenzo Pasquali; Ignasi Moran; Natalia Castro; Neil A. Hanley; José Luis Gómez-Skarmeta; Ludovic Vallier; Jorge Ferrer

The genomic regulatory programmes that underlie human organogenesis are poorly understood. Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer and diabetes. We have now characterized the regulatory landscape of embryonic multipotent progenitor cells that give rise to all pancreatic epithelial lineages. Using human embryonic pancreas and embryonic-stem-cell-derived progenitors we identify stage-specific transcripts and associated enhancers, many of which are co-occupied by transcription factors that are essential for pancreas development. We further show that TEAD1, a Hippo signalling effector, is an integral component of the transcription factor combinatorial code of pancreatic progenitor enhancers. TEAD and its coactivator YAP activate key pancreatic signalling mediators and transcription factors, and regulate the expansion of pancreatic progenitors. This work therefore uncovers a central role for TEAD and YAP as signal-responsive regulators of multipotent pancreatic progenitors, and provides a resource for the study of embryonic development of the human pancreas.


Development | 2015

Human pancreas development

Rachel Jennings; Andrew Berry; James Strutt; David T. Gerrard; Neil A. Hanley

A wealth of data and comprehensive reviews exist on pancreas development in mammals, primarily mice, and other vertebrates. By contrast, human pancreatic development has been less comprehensively reviewed. Here, we draw together those studies conducted directly in human embryonic and fetal tissue to provide an overview of what is known about human pancreatic development. We discuss the relevance of this work to manufacturing insulin-secreting β-cells from pluripotent stem cells and to different aspects of diabetes, especially permanent neonatal diabetes, and its underlying causes. Summary: This Review presents a human-centric view of the latest advances in our understanding of pancreas development and the relevance of these insights from a clinical perspective.


American Journal of Human Genetics | 2011

Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome.

Stefanie Weber; Holger Thiele; Sevgi Mir; Mohammad R. Toliat; Betul Sozeri; Heiko Reutter; Markus Draaken; Michael Ludwig; Janine Altmüller; Peter Frommolt; Helen M. Stuart; Parisa Ranjzad; Neil A. Hanley; Rachel Jennings; William G. Newman; Duncan T. Wilcox; Uwe Thiel; Karl P. Schlingmann; Rolf Beetz; Peter F. Hoyer; Martin Konrad; Franz Schaefer; Peter Nürnberg; Adrian S. Woolf

Urinary bladder malformations associated with bladder outlet obstruction are a frequent cause of progressive renal failure in children. We here describe a muscarinic acetylcholine receptor M3 (CHRM3) (1q41-q44) homozygous frameshift mutation in familial congenital bladder malformation associated with a prune-belly-like syndrome, defining an isolated gene defect underlying this sometimes devastating disease. CHRM3 encodes the M3 muscarinic acetylcholine receptor, which we show is present in developing renal epithelia and bladder muscle. These observations may imply that M3 has a role beyond its known contribution to detrusor contractions. This Mendelian disease caused by a muscarinic acetylcholine receptor mutation strikingly phenocopies Chrm3 null mutant mice.


Neuropathology and Applied Neurobiology | 2006

Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP‐17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer’s disease

A. M. Shiarli; Rachel Jennings; Jing Shi; Kathryn L. Bailey; Yvonne S. Davidson; Jinzhou Tian; Eileen H. Bigio; Bernardino Ghetti; Jill R. Murrell; Marie-Bernadette Delisle; Suzanne S. Mirra; Barbara J. Crain; Paolo Zolo; Kunimasa Arima; Eizo Iseki; Shigeo Murayama; Hans A. Kretzschmar; Manuela Neumann; Carol F. Lippa; Glenda M. Halliday; J. M. MacKenzie; Nadeem Khan; Rivka Ravid; Dennis W. Dickson; Zbigniew K. Wszolek; Takeshi Iwatsubo; S. M. Pickering-Brown; D. M. A. Mann

In order to gain insight into the pathogenesis of frontotemporal lobar degeneration (FTLD), the mean tau load in frontal cortex was compared in 34 patients with frontotemporal dementia linked to chromosome 17 (FTDP‐17) with 12 different mutations in the tau gene (MAPT), 11 patients with sporadic FTLD with Pick bodies and 25 patients with early onset Alzheimer’s disease (EOAD). Tau load was determined, as percentage of tissue occupied by stained product, by image analysis of immunohistochemically stained sections using the phospho‐dependent antibodies AT8, AT100 and AT180. With AT8 and AT180 antibodies, the amount of tau was significantly (P < 0.001 in each instance) less than that in EOAD for both FTDP‐17 (8.5% and 10.0% respectively) and sporadic FTLD with Pick bodies (16.1% and 10.0% respectively). With AT100, the amount of tau detected in FTDP‐17 was 54% (P < 0.001) of that detected in EOAD, but no tau was detected in sporadic FTLD with Pick bodies using this particular antibody. The amount of insoluble tau deposited within the brain in FTDP‐17 did not depend in any systematic way upon where the MAPT mutation was topographically located within the gene, or on the physiological or structural change generated by the mutation, regardless of which anti‐tau antibody was used. Not only does the amount of tau deposited in the brain differ between the three disorders, but the pattern of phosphorylation of tau also varies according to disease. These findings raise important questions relating to the role of aggregated tau in neurodegeneration – whether this represents an adaptive response which promotes the survival of neurones, or whether it is a detrimental change that directly, or indirectly, brings about the demize of the affected cell.


Islets | 2014

The window period of NEUROGENIN3 during human gestation.

Rachel J. Salisbury; Jennifer Blaylock; Andrew Berry; Rachel Jennings; Ronald R. de Krijger; Karen Hanley; Neil A. Hanley

The basic helix-loop-helix transcription factor, NEUROG3, is critical in causing endocrine commitment from a progenitor cell population in the developing pancreas. In human, NEUROG3 has been detected from 8 weeks post-conception (wpc). However, the profile of its production and when it ceases to be detected is unknown. In this study we have defined the profile of NEUROG3 detection in the developing pancreas to give insight into when NEUROG3-dependent endocrine commitment is possible in the human fetus. Immunohistochemistry allowed counting of cells with positively stained nuclei from 7 wpc through to term. mRNA was also isolated from sections of human fetal pancreas and NEUROG3 transcription analyzed by quantitative reverse transcription and polymerase chain reaction. NEUROG3 was detected as expected at 8 wpc. The number of NEUROG3-positive cells increased to peak levels between 10 wpc and 14 wpc. It declined at and after 18 wpc such that it was not detected in human fetal pancreas at 35–41 wpc. Analysis of NEUROG3 transcription corroborated this profile by demonstrating very low levels of transcript at 35–41 wpc, more than 10-fold lower than levels at 12–16 wpc. These data define the appearance, peak and subsequent disappearance of the critical transcription factor, NEUROG3, in human fetal pancreas for the first time. By inference, the window for pancreatic endocrine differentiation via NEUROG3 action opens at 8 wpc and closes between 21 and 35 wpc.


eLife | 2016

An integrative transcriptomic atlas of organogenesis in human embryos

Dave T. Gerrard; Andrew Berry; Rachel Jennings; Karen Hanley; Nicoletta Bobola; Neil A. Hanley

Human organogenesis is when severe developmental abnormalities commonly originate. However, understanding this critical embryonic phase has relied upon inference from patient phenotypes and assumptions from in vitro stem cell models and non-human vertebrates. We report an integrated transcriptomic atlas of human organogenesis. By lineage-guided principal components analysis, we uncover novel relatedness of particular developmental genes across different organs and tissues and identified unique transcriptional codes which correctly predicted the cause of many congenital disorders. By inference, our model pinpoints co-enriched genes as new causes of developmental disorders such as cleft palate and congenital heart disease. The data revealed more than 6000 novel transcripts, over 90% of which fulfil criteria as long non-coding RNAs correlated with the protein-coding genome over megabase distances. Taken together, we have uncovered cryptic transcriptional programs used by the human embryo and established a new resource for the molecular understanding of human organogenesis and its associated disorders. DOI: http://dx.doi.org/10.7554/eLife.15657.001


Diabetes | 2015

Altered Phenotype of β-Cells and Other Pancreatic Cell Lineages in Patients With Diffuse Congenital Hyperinsulinism in Infancy Caused by Mutations in the ATP-Sensitive K-Channel

Rachel J. Salisbury; Bing Han; Rachel Jennings; Andrew Berry; Adam Stevens; Zainab Mohamed; Sarah A. Sugden; Ronald R. de Krijger; Sarah E. Cross; Paul P.V. Johnson; Melanie Newbould; Karen E. Cosgrove; Karen Hanley; Indraneel Banerjee; Mark J. Dunne; Neil A. Hanley

Diffuse congenital hyperinsulinism in infancy (CHI-D) arises from mutations inactivating the KATP channel; however, the phenotype is difficult to explain from electrophysiology alone. Here we studied wider abnormalities in the β-cell and other pancreatic lineages. Islets were disorganized in CHI-D compared with controls. PAX4 and ARX expression was decreased. A tendency toward increased NKX2.2 expression was consistent with its detection in two-thirds of CHI-D δ-cell nuclei, similar to the fetal pancreas, and implied immature δ-cell function. CHI-D δ-cells also comprised 10% of cells displaying nucleomegaly. In CHI-D, increased proliferation was most elevated in duct (5- to 11-fold) and acinar (7- to 47-fold) lineages. Increased β-cell proliferation observed in some cases was offset by an increase in apoptosis; this is in keeping with no difference in INSULIN expression or surface area stained for insulin between CHI-D and control pancreas. However, nuclear localization of CDK6 and P27 was markedly enhanced in CHI-D β-cells compared with cytoplasmic localization in control cells. These combined data support normal β-cell mass in CHI-D, but with G1/S molecules positioned in favor of cell cycle progression. New molecular abnormalities in δ-cells and marked proliferative increases in other pancreatic lineages indicate CHI-D is not solely a β-cell disorder.


Stem cell reports | 2017

Laser Capture and Deep Sequencing Reveals the Transcriptomic Programmes Regulating the Onset of Pancreas and Liver Differentiation in Human Embryos

Rachel Jennings; Andrew Berry; David T. Gerrard; Stephen J. Wearne; James Strutt; Sarah Withey; Mariya Chhatriwala; Karen Hanley; Ludovic Vallier; Nicoletta Bobola; Neil A. Hanley

Summary To interrogate the alternative fates of pancreas and liver in the earliest stages of human organogenesis, we developed laser capture, RNA amplification, and computational analysis of deep sequencing. Pancreas-enriched gene expression was less conserved between human and mouse than for liver. The dorsal pancreatic bud was enriched for components of Notch, Wnt, BMP, and FGF signaling, almost all genes known to cause pancreatic agenesis or hypoplasia, and over 30 unexplored transcription factors. SOX9 and RORA were imputed as key regulators in pancreas compared with EP300, HNF4A, and FOXA family members in liver. Analyses implied that current in vitro human stem cell differentiation follows a dorsal rather than a ventral pancreatic program and pointed to additional factors for hepatic differentiation. In summary, we provide the transcriptional codes regulating the start of human liver and pancreas development to facilitate stem cell research and clinical interpretation without inter-species extrapolation.

Collaboration


Dive into the Rachel Jennings's collaboration.

Top Co-Authors

Avatar

Neil A. Hanley

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Andrew Berry

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Karen Hanley

University of Manchester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David T. Gerrard

Manchester Academic Health Science Centre

View shared research outputs
Top Co-Authors

Avatar

Ignasi Moran

Imperial College London

View shared research outputs
Top Co-Authors

Avatar

James Strutt

University of Manchester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jorge Ferrer

Imperial College London

View shared research outputs
Top Co-Authors

Avatar

Ludovic Vallier

Wellcome Trust Sanger Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge